<span style="color: #222222;">The CSIR- Centre for Cellular and Molecular Biology has developed, possibly the first specific drug for COVID-19 treatment, which contain therapeutic antibodies.</span><br />'' <span style="color: #222222;"> </span><br />'' <span style="color: #222222;">The Drug Controller General of India (DGCI) has given its approval for human trials, Phase-I and Phase-II for the VINCOV-19 and expected to be tried next week in Delhi and Rajasthan.</span><br />'' <span style="color: #222222;"> </span><br />'' <span style="color: #222222;">Developed by the CCMB, University of Hyderabad and Vins Bioproduct ltd combine, the VINCOV-19 is a collection of antibodies from Horses after they got injected inactivated Corona virus.</span><br />'' <span style="color: #222222;"> </span><br />'' <span style="color: #222222;">CCMB Director Dr Rakesh K Mishra informed our Hyderabad correspondent that the approval for its emergency use by the India's Drug Regulator is expected once the results of phase I and II declared.</span><br />'' <span style="color: #222222;"> </span><br />'' <span style="color: #222222;">He exuded confidence that it may take 3-4 weeks for getting approval for emergency use.</span><br />'' <span style="color: #222222;"> </span><br />'' <span style="color: #222222;">He further said the VINCOV may be the first specific drug for COVID treatment and it works best when given on early stage of infection.</span><br />''  <br />